Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
This study has been completed.
Sponsor:
Shire
ClinicalTrials.gov Identifier:
NCT00882687
First Posted: April 16, 2009
Last Update Posted: February 24, 2017
Information provided by (Responsible Party):
Shire
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
| Condition | Intervention | Phase |
|---|---|---|
| Allergic Conjunctivitis | Drug: Lifitegrast Other: Placebo | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model |
Resource links provided by NLM:
Further study details as provided by Shire:
Primary Outcome Measures:
- Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6]) [ Time Frame: Baseline to Day 7 (7 minutes post CAC 6) ]Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching. CAC is an initial titration challenge to determine the appropriate allergen and lowest concentration of allergen that produced a positive bilateral allergic response for each subject, defined as ≥ 2 score (0-4 point scale) in ocular itching and conjunctival redness within 10 minutes of the last titration of allergen.
- Ocular Itching at Day 14 (7 Minutes Post CAC 9) [ Time Frame: Baseline to Day 14 (7 minutes post CAC 9) ]Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching.
- Conjunctival Redness at Day 7 (20 Minutes Post CAC 6) [ Time Frame: Baseline to Day 7 (20 minutes post CAC 6) ]Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.
- Conjunctival Redness at Day 14 (20 Minutes Post CAC 9) [ Time Frame: Baseline to Day 14 (20 minutes post CAC 9) ]Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.
Secondary Outcome Measures:
- Ocular Itching at Day 6 (CAC 4), 5 (CAC 7) [ Time Frame: Baseline to Day 6 (CAC 4), Day 13 (CAC 7) 7 minutes post CAC ]Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching.
- Conjunctival Redness at Day 6 (CAC 4), 5 (CAC 7) [ Time Frame: Baseline to Day 6 (CAC 4), Day 13 (CAC 7) at 20 minutes post CAC ]Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.
| Enrollment: | 60 |
| Study Start Date: | April 2009 |
| Study Completion Date: | May 2009 |
| Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 0.1% Lifitegrast |
Drug: Lifitegrast
Ophthalmic Solution
Other Name: SAR 1118
|
| Experimental: 1.0% Lifitegrast |
Drug: Lifitegrast
Ophthalmic Solution
Other Name: SAR 1118
|
| Experimental: 5.0% Lifitegrast |
Drug: Lifitegrast
Ophthalmic Solution
Other Name: SAR 1118
|
| Placebo Comparator: Placebo |
Other: Placebo
Ophthalmic Solution
|
Eligibility
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Signed informed consent form and HIPAA document
- Willing and able to comply with all study procedures
- Be at least 18 years of age at the time of enrollment
- 20/40 vision, or better, in each eye
- History of ocular allergies, and a positive skin and ocular allergic reaction to allergens
- A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period
Exclusion Criteria:
- Preauricular lymphadenopathy or any ocular condition that could affect study parameters (particularly, glaucoma, diabetic retinopathy, clinically significant blepharitis, follicular conjunctivitis and iritis)
- Have had any ocular infection within the last 30 days
- A positive diagnosis of moderate to severe dry eye syndrome (i.e., requiring daily use of artificial tears)
- Any significant illness that could be expected to interfere with study parameters
- Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye
- Use of any investigational product or device within one month prior to Visit 1 or during the study period
- Concomitant use of any prohibited medication (antihistamines, corticosteroids, all ocular medications or anti-allergic therapies) during the trial or within the washout period
- Any blood donation or significant loss of blood within 56 days of Visit 1
- Any history of autoimmune disease, immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti‑HAV IgM), or organ or bone marrow transplant. Any known history of iritis/uveitis, glaucoma, or other chronic ophthalmologic disorder other than allergic conjunctivitis
- History of laser‑assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 3 months prior to Visit 1
- Known history of alcohol abuse and/or drug abuse
Contacts and Locations
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00882687
Locations
| United States, Massachusetts | |
| Ora | |
| Andover, Massachusetts, United States, 01810 | |
Sponsors and Collaborators
Shire
Investigators
| Principal Investigator: | Gail Torkildsen, MD | ORA, Inc. |
More Information
| Responsible Party: | Shire |
| ClinicalTrials.gov Identifier: | NCT00882687 History of Changes |
| Other Study ID Numbers: |
1118-ACJ-100 |
| First Submitted: | April 15, 2009 |
| First Posted: | April 16, 2009 |
| Results First Submitted: | November 6, 2015 |
| Results First Posted: | February 24, 2017 |
| Last Update Posted: | February 24, 2017 |
| Last Verified: | January 2017 |
Additional relevant MeSH terms:
|
Conjunctivitis Conjunctivitis, Allergic Conjunctival Diseases Eye Diseases Hypersensitivity, Immediate |
Hypersensitivity Immune System Diseases Ophthalmic Solutions Pharmaceutical Solutions |